Theralase Technologies Inc. (TLT) | WebDisclosure

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Headlines Articles Press releases Theralase Technologies Inc.

Home
Companies
Theralase Technologies Inc.

PRESS RELEASE

published on 02/08/2024 at 13:00, 9 months 13 days ago

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval

Clinical Study Regulatory Approval Theralase® Technologies Inc. Dr. Michael Jewett Enrollment
PRESS RELEASE

published on 02/05/2024 at 22:35, 9 months 16 days ago

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase Technologies Inc. has closed a non-brokered private placement offering of units, raising approximately $CAN 1,200,000 for cancer research and development. The company plans to use the funds for clinical study, preclinical research, and general corporate purposes

Pharmaceutical Company Private Placement Offering Theralase Technologies Inc. Clinical Study Cancer Research
PRESS RELEASE

published on 01/15/2024 at 13:00, 10 months 6 days ago

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027.

Theralase Technologies Inc. Bladder Cancer Clinical Study Break Through Designation Accelerated Approval Health Canada And FDA Approval
PRESS RELEASE

published on 11/30/2023 at 00:30, 11 months 21 days ago

Theralase Release’s 3Q2023 Interim Financial Statements
Theralase Technologies Inc. has released the Company's 3Q2023 unaudited condensed interim consolidated Financial Statements, showing a 13% decrease in total revenue and other significant financial highlights

Financial Statements Theralase Technologies Inc. Clinical Research 3Q2023 Revenue Decrease
PRESS RELEASE

published on 11/29/2023 at 22:35, 11 months 22 days ago

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
PRESS RELEASE

published on 11/17/2023 at 22:30, 1 year ago

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
PRESS RELEASE

published on 10/23/2023 at 23:55, 1 year ago

Theralase(R) Announces Brokered LIFE Financing
PRESS RELEASE

published on 10/23/2023 at 13:00, 1 year ago

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
PRESS RELEASE

published on 10/16/2023 at 13:00, 1 year 1 month ago

Theralase(R) Provides Update on Bladder Cancer Clinical Study
PRESS RELEASE

published on 10/05/2023 at 13:00, 1 year 1 month ago

Theralase(R) Files US Patent for Enhanced Immunotherapy

Accesswire

Published on 11/21/2024 at 22:05, 44 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 59 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 34 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 39 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 2 hours 49 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 3 hours 47 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 13 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 4 hours 50 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 4 hours 57 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 4 hours 57 minutes ago

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.

Les Echos

Published on 11/21/2024 at 06:58, 15 hours 51 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 15 hours 51 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 15 hours 51 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 2 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 3 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE